Gastrointestinal acute graft-versus-host disease
MaaT PHARMA focuses on gastrointestinal acute graft-versus-host disease, with research directed toward treatment-resistant inflammatory complications affecting the digestive tract after allogeneic hematopoietic cell transplantation.
- Salvage therapy for GI-aGvHD
- Ruxolitinib-refractory disease
- Intestinal immune dysregulation
Its clinical activity includes patients with severe GI-aGvHD who have limited response to prior therapies, reflecting a strong therapeutic interest in post-transplant inflammatory disease.
Allogeneic hematopoietic cell transplantation complications
The sponsor also studies complications associated with allogeneic hematopoietic cell transplantation in patients with hematologic malignancies, particularly immune-mediated outcomes that affect survival and recovery.
- Post-transplant complication prevention
- Overall survival in transplant recipients
- Hematologic malignancy support care
Research in this area links transplant medicine with management of complications that arise after cellular therapy for blood cancers.
Microbiome-based therapeutic approaches
MaaT PHARMA is active in microbiome-based medicine, including orally administered pooled fecal microbiotherapy for prevention of transplant-related complications and immune injury.
- Oral microbiotherapy
- Gut microbiome restoration
- Immune-microbiota interaction
This area connects intestinal microbial balance with control of post-transplant inflammatory syndromes.
Pediatric gastrointestinal transplantation disorders
The sponsor’s research also extends to pediatric patients with GI-aGvHD, addressing safety, tolerability, and feasibility of treatment in children and adolescents affected by severe post-transplant disease.
- Pediatric GI-aGvHD
- Adolescent transplant care
- Safety and tolerability in children
This clinical interest highlights the need for age-appropriate approaches in transplant-related gastrointestinal inflammation.
